Novo Nordisk's Step Young Pediatric Trial Meets Primary Endpoint

Novo Nordisk's Phase 3 Step Young trial met its primary endpoint, showing that weekly semaglutide plus lifestyle changes reduced BMI more than placebo in children aged 6 to under 12. This is a positive clinical readout for the company's pediatric obesity franchise, though regulatory and reimbursement hurdles remain. The result could support label expansion and strengthen Novo Nordisk's competitive position in the pediatric obesity market.